Dealmaking has long been a hallmark of the biopharma industry, playing a crucial role in most firms’ growth strategies. Historically, the sector has seen more and bigger transactions than even the tech industry. Because innovation comes slowly in biopharma, mergers, acquisitions, and other partnerships to boost the new-product pipeline have been an existential necessity for successful companies. That’s been especially evident in recent years—with some notable shifts.
Read the full article: Five Ways Biopharma Companies Can Navigate the Deal Landscape //
Source: https://www.mckinsey.com/industries/life-sciences/our-insights/five-ways-biopharma-companies-can-navigate-the-deal-landscape